NASDAQ: CCCCC4 Therapeutics Inc Stock
$6.24-0.23 (-3.55%)
Updated Apr 25, 2024
CCCC Price
$6.24
Fair Value Price
-$1.21
Market Cap
$428.07M
52 Week Low
$1.06
52 Week High
$11.88
P/E
-2.34x
P/B
1.74x
P/S
13.51x
PEG
N/A
Dividend Yield
N/A
Revenue
$20.76M
Earnings
-$132.49M
Gross Margin
100%
Operating Margin
-625.55%
Profit Margin
-638.3%
Debt to Equity
0.53
Operating Cash Flow
-$107M
Beta
1.95
Next Earnings
Jun 14, 2024
Ex-Dividend
N/A
Next Dividend
N/A
CCCC Overview
C4 Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing therapies to degrade disease-causing proteins and thereby treat cancer, neurodegenerative conditions, and other diseases. The company uses its TORPEDO platform to synthesize targeted small molecule protein degraders, which employ a natural protein disposal system to catalyze the destruction of target proteins. C4 Therapeutics has strategic collaborations with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. The company was incorporated in 2015 and is headquartered in Watertown, MA.
Zen Score
–
Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how CCCC scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
CCCC ($6.24) is overvalued by 616.37% relative to our estimate of its Fair Value price of -$1.21 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
CCCC ($6.24) is not significantly undervalued (616.37%) relative to our estimate of its Fair Value price of -$1.21 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
CCCC is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more CCCC due diligence checks available for Premium users.
Be the first to know about important CCCC news, forecast changes, insider trades & much more!
CCCC News
Valuation
CCCC fair value
Fair Value of CCCC stock based on Discounted Cash Flow (DCF)
Price
$6.24
Fair Value
-$1.21
Undervalued by
616.37%
CCCC ($6.24) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
CCCC ($6.24) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
CCCC is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
CCCC price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-2.34x
Industry
15.41x
Market
40.97x
CCCC price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
1.74x
Industry
5.8x
CCCC is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
CCCC's financial health
Profit margin
Revenue
$3.3M
Net Income
-$34.8M
Profit Margin
-1,065.7%
CCCC's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
CCCC's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$376.5M
Liabilities
$130.3M
Debt to equity
0.53
CCCC's short-term assets ($271.19M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
CCCC's short-term assets ($271.19M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
CCCC's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
CCCC's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$24.0M
Investing
$31.9M
Financing
$57.7M
CCCC's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
CCCC vs Biotech Stocks
C4 Therapeutics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.